Baricitinib in Patients With Relapsing or naïve Dermatomyositis
A legfontosabb adatok
- Ki végzi
- Assistance Publique - Hôpitaux de Paris
- Hol
- Franciaország17 helyszín, 1 országbanVálassz országot a helyszínekhez
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 62 fő, tervezett
- Kezdés
- 2022. aug. 31.
- Várható befejezés
- 2028. febr. 28.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Baricitinib
- Placebo
- A regiszteradat frissítve
- 2026. június 2.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with active dermatomyositis, either newly diagnosed and untreated or relapsing. It tests baricitinib or placebo added to usual care.
- Életkor
- 18 to 64 years (at least 18 and under 65 years old).
- Nem
- All sexes can join.
- A betegség stádiuma
- Dermatomyositis by the 239th ENMC criteria, active by ACR/EULAR criteria. Activity means weak muscles (MMT-8 <145/150) or skin disease (CDASI > 20), plus at least two other abnormal measures.
- Korábbi kezelés
- New or relapsing patients can join. Relapsing patients taking prednisone need a stable dose < 30 mg/d for at least 4 weeks. Other immune-suppressing drugs must be at a stable dose for at least 3 months. No rituximab within 6 months. No IVIg or cyclophosphamide within the month before. Untreated patients cannot have had more than 2 weeks of corticosteroids at 1 mg/kg/d. People in whom both methotrexate and azathioprine failed cannot join.
A részvétel fő kizáró okai
- Life-threatening complications, such as severe swallowing trouble, severe lung disease, heart muscle inflammation or loss of walking.
- Past blood clots, heart attack or ischemic stroke, or current or past long-time smoking.
- Active cancer or past cancer, severe infection, or latent tuberculosis.
- Pregnancy, breastfeeding, or planning a pregnancy.
- Kidney clearance < 60 ml, or severe liver problems.
A regiszter feltételei, szó szerint
Mind a 30 feltétel megnézéseKevesebb
Ki vehet részt
- Adult subjects (≥ 18 years old) < 65 years old
- Dermatomyositis defined according to the 239th ENMC criteria either naïve or non-naïve DM
- Active disease (ACR/EULAR criteria) defined as :; Manual Muscle Testing (MMT-8) <145/150 and at least two additional abnormal corset measurements (CSM): >3/10 cm on Visual Analogue Scale (VAS) of patient global, physician global and extra-muscular disease activity, Health Assessment Questionnaire Disability Index >0.25, or elevated muscle enzymes; Or cutaneous CDASI > 20 and at least two additional abnormal corset measurements (CSM): >3/10 cm on Visual Analogue Scale (VAS) of patient global, physician global and extra-muscular disease activity, Health Assessment Questionnaire Disability Index >0.25, or elevated muscle enzymes
- for relapsing/non naïve DM patients :; in case of corticosteroid exposure patient must receive a stable dose < 30 mg/d prednisone with or without additional immunosuppressive therapy for at least 4 weeks before the baseline visit; Stable dose of immunosuppressive therapy for at least 3 months before
- Affiliation to a social security regime
- Written informed consent
Ki nem vehet részt
- Strong Organic Anion Transporter 3 (OAT3) inhibitors
- Previous treatment exposure defined as follow : • Rituximab treatment within 6months before inclusion; IVIg, or cyclophosphamide infusion within the month before inclusion; both methotrexate (0.3 mg/kg/w) and azathioprine exposure for at least 3 months each and at the 0.3 mg/kg/w and 2-3 mg/kg/d dosages respectively with failure of both (but exposure and/or failure to either of these two drugs alone is not an exclusion criterion); for naïve DM patients only, more than 2 weeks treatment duration with corticosteroids at the dose of 1 mg/kg/d before the inclusion
- Severe disease damages: e.g. muscle weakness mainly related to muscle damage such as fat replacement of muscle) defined as persistent changes in anatomy, physiology, pathology or function which result from previously active disease and from complications of therapy or other events (e.g.; muscle atrophy, fatty replacement; skin scars, poikiloderma ). Severe disease damage is considered when the patient condition has no or minor ability to improve with the treatment
- Life-threatening complications :; Severe swallowing troubles defined as: food swallowed the wrong way and/or time to drink a glass of 200 ml water above 30 seconds related to DM; Interstitial lung disease related to the DM with one among the following complications (complications must be related to the ILD): dyspnea NYHA III, hypoxemia with PaO2≤65 mmHg, and/or DLCOc/Alveolar Volume ≤70% (pulmonary function test); Symptomatic myocarditis o Loss of walking ability
- Patient with deep vein thrombosis/pulmonary embolism or antecedent
- Patient with antecedent of cardiovascular event (myocardial infarction or ischemic stroke)
- Active cancer or history of malignancy
- Active severe infection including active hepatitis
- Evidence of latent tuberculosis (as documented by a positive QuantiFERON-TB Gold plus test)
- Severe hepatic impairment attested by FV (coagulation factor)<30%
- Liver insufficiency (Prothrombin time <60%)
- Hypersensitivity to the active substance (baricitinib) or to any of the excipients
- Contraindication to Methotrexate and/or Azathioprine including hypersensitivity to the active substances or to any of the excipients
- Conditions affecting the outcomes (Expected poor compliance)
- Renal impairment defined as clearance < 60 ml
- Absolute Neutrophil Count < 1x109 cells/L
- Haemoglobin (Hb) < 8 g/dL
- Significant uncontrolled cardiovascular, cerebrovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neuropsychiatric disorders, or abnormal laboratory values that developed during a qualifying study that, in the opinion of the investigator, poses an unacceptable risk for the patient's participation
- No effective contraception during the study and one week after for women of childbearing age
- Patient who is current or past long-time smoker
- Pregnant or lactating, or women planning to become pregnant or initiating breastfeeding
- Chest imaging (CT scan or radiograph) showing abnormalities not related with the DM in the last 12 weeks judged by the investigator as clinically significant
- Participants included in other intervention research involving humans
- Patient under tutorship or guardianship, and incapable to give informed consent
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 64 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Franciaország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Dermatomyositis (DM) is a rare and disabling condition with an important impairment of quality of life and possible life-threatening complications.
A teljes eredeti leírásKevesebb
Treatment is based on high doses of corticosteroids but this exposes patients to adverse events (cardiovascular mortality, glucocorticoids-induced muscle and skin damages). Corticosteroids taper is associated with disease relapses. Although there is no evidence from the literature, clinical practice guidelines recommends the use of DMARDs such as methotrexate. However, response is not complete and these DMARDS take time to act.
The interferon type I (IFN-I) pathway is involved in the pathophysiology of DM. Janus kinase 1 and 2 transduces IFN-I signals. In addition, JAK2 inhibition enhances muscle repair and force generation.
JAK 1/2 inhibitors permitted to dramatically and rapidly improve relapsing DM patients (n=4, case series).
Our hypothesis is that Janus kinase 1 and 2 (JAK1/2) inhibitors (baricitinib) will permit to obtain dermatomyositis (DM) improvement with a steroid sparing effect as compared to usual care.
Our primary objective is to evaluate the efficacy of baricitinib (JAK1/2 inhibitor) to obtain prednisone-free moderate improvement (ACR/EULAR ≥ 40) of DM as compared to placebo in addition to usual care.
BIRD is a multicenter phase III double blind randomized placebo-controlled trial with two parallel arms (1:1). This is an add-on trial to usual care with rapid corticoid taper.
This is a multicenter trial in different medical departments in hospitals across France in different regions.
Out- and in patients will be recruited in hospital departments involved in management and diagnosis of DM: departments of dermatology, rheumatology and internal medicine.
A vizsgálat 2 csoportja
- baricitinib armA vizsgált kezelés
Patients receive baricitinib plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
Kezelés: Baricitinib
- placebo armPlacebo, összehasonlításként
Patients receive placebo plus prednisone taper plus one immunosuppressive drug (either methotrexate or azathioprine) for a duration of 24 weeks. Corticosteroids are tapered following a predefined protocol.
Kezelés: Placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Baricitinib in Patients With Relapsing or naïve Dermatomyositis: a Multicenter Randomized Controlled Trial (BIRD)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT04972760: ki vehet részt
- A regiszteradat frissítve
- 2026. június 2.